Given that YIV-818-A, RA-V, or RA-VII exhibit distinct mechanisms of action in inhibiting AR compared to the FDA-approved androgen inhibitors, enzalutamide, apalutamide, and darolutamide used in prostate cancer treatments, we speculated that YIV-818-A, RA-V, or RA-VII might have the potential to synergistically enhance the therapeutic effects of enzalutamide, apalutamide, or darolutamide. Here, AR is linked to prostate carcinoma.